Eyenovia, Inc. (EYEN)

NASDAQ: EYEN · Real-Time Price · USD
0.500
-0.008 (-1.59%)
At close: Sep 18, 2024, 4:00 PM
0.510
+0.010 (2.00%)
After-hours: Sep 18, 2024, 7:35 PM EDT
-1.59%
Market Cap 38.45M
Revenue (ttm) 31,405
Net Income (ttm) -37.28M
Shares Out 76.91M
EPS (ttm) -0.79
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 606,112
Open 0.505
Previous Close 0.508
Day's Range 0.500 - 0.545
52-Week Range 0.370 - 2.570
Beta 1.74
Analysts Strong Buy
Price Target 10.00 (+1,900.0%)
Earnings Date Nov 11, 2024

About EYEN

Eyenovia, Inc., a commercial-stage ophthalmic pharmaceutical technology company, engages in developing a pipeline of microdose array print therapeutics. It focuses on commercializing Mydcombi (tropicamide and phenylephrine HCL ophthalmic spray) for inducing mydriasis for routine diagnostic procedures and in conditions where short term pupil dilation is desired, and clobetasol propionate ophthalmic suspension for the treatment of post-operative pain and inflammation following ocular surgery. The company is also developing the Optejet delivery sy... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 25, 2018
Employees 57
Stock Exchange NASDAQ
Ticker Symbol EYEN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for EYEN stock is "Strong Buy." The 12-month stock price forecast is $10.0, which is an increase of 1,900.00% from the latest price.

Price Target
$10.0
(1,900.00% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Formosa Pharmaceuticals Makes First Shipment of APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%) to the United States for Commercialization

TAIPEI , Sept. 9, 2024 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (hereinafter referred to as "Formosa Pharma," 6838.TW) announced the successful first shipment to the United States of its new opht...

9 days ago - PRNewsWire

Eyenovia Announces Taiwan Export License Approval to Commence Shipment of Clobetasol Propionate Ophthalmic Suspension (0.05%) to the U.S.

Eyenovia is planning for a U.S. launch for Clobetasol in late September 2024 Eyenovia is planning for a U.S. launch for Clobetasol in late September 2024

13 days ago - GlobeNewsWire

Eyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial Officer

Current CFO, John Gandolfo, to remain with the Company through November as part of planned retirement transition Current CFO, John Gandolfo, to remain with the Company through November as part of plan...

15 days ago - GlobeNewsWire

Eyenovia Announces Closing of Public Offering

NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today the closing of its public offering of 12...

26 days ago - GlobeNewsWire

Why Is Eye Disease Focused Eyenovia Stock Trading Higher On Thursday?

Eyenovia Inc EYEN stock is trading higher on Thursday after its plunge yesterday, with a session volume of 6.7 million, versus an average volume of 1.33 as per data from Benzinga Pro.

27 days ago - Benzinga

Eyenovia Announces Pricing of $5.14 Million Public Offering

NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today that it has agreed to sell 12,850,000 sh...

4 weeks ago - GlobeNewsWire

Eyenovia, Inc. Announces Proposed Public Offering

NEW YORK, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today that it intends to offer and sell shares...

4 weeks ago - GlobeNewsWire

Eyenovia, Inc. (EYEN) Q2 2024 Earnings Call Transcript

Eyenovia, Inc. (NASDAQ:EYEN) Q2 2024 Earnings Conference Call August 12, 2024 4:30 PM ET Company Participants Eric Ribner - IR Michael Rowe - Chief Executive Officer Bren Kern - Chief Operating Offic...

5 weeks ago - Seeking Alpha

Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Following FDA consultation, announced plans for validation of the Gen-2 Optejet® device and 2025 regulatory submission with Mydcombi™ as lead product

5 weeks ago - GlobeNewsWire

Eyenovia to Report Second Quarter 2024 Results on Monday, August 12th

Company to host an investor conference call and webcast at 4:30pm EDT Company to host an investor conference call and webcast at 4:30pm EDT

5 weeks ago - GlobeNewsWire

Eyenovia and Formosa Pharmaceuticals Initiate Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S.

Product-candidate would incorporate new steroid with the Optejet® for the millions of dry eye patients who experience periodic flare-ups Product-candidate would incorporate new steroid with the Opteje...

6 weeks ago - GlobeNewsWire

Formosa Pharma and Eyenovia Announce Initiation of Co-Development of Clobetasol Propionate Ophthalmic Suspension, 0.05%, for the treatment of Acute Dry Eye Disease in United States

TAIPEI , Aug. 7, 2024 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TWO) announced today that the company has signed a non-binding terms agreement with Eyenovia, Inc. ("Eyenovi...

6 weeks ago - PRNewsWire

Eyenovia & SGN Nanopharma Announce Collaboration Agreement to Develop Novel Treatment for Chronic Dry Eye Disease

The U.S. addressable market for Dry Eye Disease is valued at over $3 billion by independent sources The U.S. addressable market for Dry Eye Disease is valued at over $3 billion by independent sources

7 weeks ago - GlobeNewsWire

Eyenovia and Senju Pharmaceutical Co., Ltd. Sign Collaboration Agreement for Potential New Treatment for Chronic Dry Eye Disease

Collaboration to focus on the development of a formulation of Senju's SJP-0035 for use with Eyenovia's Optejet® dispensing technology, following consultation with FDA

2 months ago - GlobeNewsWire

NovaBay Pharmaceuticals and Eyenovia Commence Co-Promotion Activities

EMERYVILLE, Calif. & NEW YORK--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare products, and Eyenovia, Inc. (NASDAQ:...

Other symbols: NBY
2 months ago - Business Wire

Eyenovia Announces Pricing of $5M Registered Direct Offering

NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today that it has entered into a securities pu...

2 months ago - GlobeNewsWire

Eyenovia, Inc. (EYEN) Q1 2024 Earnings Call Transcript

Eyenovia, Inc. (NASDAQ:EYEN) Q1 2024 Results Conference Call May 14, 2024 4:30 PM ET Company Participants Eric Ribner - IR Michael Rowe - Chief Executive Officer John Gandolfo - Chief Financial Offic...

4 months ago - Seeking Alpha

Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol

Remains on track towards accelerating development of its late-stage product candidate in the multi-billion-dollar pediatric progressive myopia market, MicroPine

4 months ago - GlobeNewsWire

Eyenovia to Report First Quarter 2024 Results on Wednesday, May 15th

Company to host an investor conference call and webcast at 4:30pm EDT Company to host an investor conference call and webcast at 4:30pm EDT

4 months ago - GlobeNewsWire

Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension

Company announces results from a Phase IV study of Mydcombi designed to characterize the efficacy and duration of the lowest deliverable dose (one 8µL spray per eye)

5 months ago - GlobeNewsWire

Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company, today announced its plans for accelerating development of its potential multi-billion...

5 months ago - GlobeNewsWire

Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings

Company to demonstrate Mydcombi™ and Avenova® and Share Data for Clobetasol Propionate Ophthalmic Suspension 0.05% at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, Ap...

6 months ago - GlobeNewsWire

Eyenovia, Inc. (EYEN) Q4 2023 Earnings Call Transcript

Eyenovia, Inc. (EYEN) Q4 2023 Earnings Call Transcript

6 months ago - Seeking Alpha

Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Announced FDA approval of clobetasol propionate ophthalmic suspension 0.05% for post-operative pain and inflammation following ocular surgery

6 months ago - GlobeNewsWire

NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals

EMERYVILLE, Calif. and NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Eyenovia, Inc. (Nasdaq: EYEN) announced the signing of a co-promotion agreeme...

6 months ago - GlobeNewsWire